Snake Bite in South Asia: A Review

Snake bite is one of the most neglected public health issues in poor rural communities living in the tropics. Because of serious misreporting, the true worldwide burden of snake bite is not known. South Asia is the world's most heavily affected region, due to its high population density, widespread agricultural activities, numerous venomous snake species and lack of functional snake bite control programs. Despite increasing knowledge of snake venoms' composition and mode of action, good understanding of clinical features of envenoming and sufficient production of antivenom by Indian manufacturers, snake bite management remains unsatisfactory in this region. Field diagnostic tests for snake species identification do not exist and treatment mainly relies on the administration of antivenoms that do not cover all of the important venomous snakes of the region. Care-givers need better training and supervision, and national guidelines should be fed by evidence-based data generated by well-designed research studies. Poorly informed rural populations often apply inappropriate first-aid measures and vital time is lost before the victim is transported to a treatment centre, where cost of treatment can constitute an additional hurdle. The deficiency of snake bite management in South Asia is multi-causal and requires joint collaborative efforts from researchers, antivenom manufacturers, policy makers, public health authorities and international funders

Design and baseline characteristics of the finerenone in reducing cardiovascular mortality and morbidity in diabetic kidney disease trial

Background: Among people with diabetes, those with kidney disease have exceptionally high rates of cardiovascular (CV) morbidity and mortality and progression of their underlying kidney disease. Finerenone is a novel, nonsteroidal, selective mineralocorticoid receptor antagonist that has shown to reduce albuminuria in type 2 diabetes (T2D) patients with chronic kidney disease (CKD) while revealing only a low risk of hyperkalemia. However, the effect of finerenone on CV and renal outcomes has not yet been investigated in long-term trials. Patients and Methods: The Finerenone in Reducing CV Mortality and Morbidity in Diabetic Kidney Disease (FIGARO-DKD) trial aims to assess the efficacy and safety of finerenone compared to placebo at reducing clinically important CV and renal outcomes in T2D patients with CKD. FIGARO-DKD is a randomized, double-blind, placebo-controlled, parallel-group, event-driven trial running in 47 countries with an expected duration of approximately 6 years. FIGARO-DKD randomized 7,437 patients with an estimated glomerular filtration rate >= 25 mL/min/1.73 m(2) and albuminuria (urinary albumin-to-creatinine ratio >= 30 to <= 5,000 mg/g). The study has at least 90% power to detect a 20% reduction in the risk of the primary outcome (overall two-sided significance level alpha = 0.05), the composite of time to first occurrence of CV death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure. Conclusions: FIGARO-DKD will determine whether an optimally treated cohort of T2D patients with CKD at high risk of CV and renal events will experience cardiorenal benefits with the addition of finerenone to their treatment regimen. Trial Registration: EudraCT number: 2015-000950-39; ClinicalTrials.gov identifier: NCT02545049

Measurement of Ωc0\Omega^0_{\rm c} baryon production and branching-fraction ratio BR(Ωc0→Ω−e+νe)/BR(Ωc0→Ω−π+){\rm BR(\Omega^0_c \rightarrow \Omega^- e^+\nu_e)} / {\rm BR(\Omega^0_c \rightarrow \Omega^- \pi^+)} in pp collisions at s\sqrt{s} = 13 TeV

International audienceThe inclusive production of the charm-strange baryon $\Omega^{0}_{\rm c}$ is measured for the first time via its semileptonic decay into $\Omega^{-}\rm e^{+}\nu_{e}$ at midrapidity ($|y|<0.8$) in proton$-$proton (pp) collisions at the centre-of-mass energy $\sqrt{s}=13$ TeV with the ALICE detector at the LHC. The transverse momentum ($p_{\rm T}$) differential cross section multiplied by the branching ratio is presented in the interval $2<p_{\rm T}<12~{\rm GeV}/c$. The branching-fraction ratio ${\rm BR}(\Omega^0_{\rm c} \rightarrow \Omega^{-}{\rm e}^{+}\nu_{\rm e})/ {\rm BR}(\Omega^0_{\rm c} \rightarrow \Omega^{-}{\pi}^{+})$ is measured to be 1.12 $\pm$ 0.22 (stat.) $\pm$ 0.27 (syst.). Comparisons with other experimental measurements, as well as with theoretical calculations, are presented